By Conor Coyle
Date: Monday 24 Oct 2016
(ShareCast News) - The Food and Drug Administration's decision to place Aduro Biotech's clinical trials on hold triggered a short-lived plunge in the company's shares on Monday.
No recent information was found.
| Currency | US Dollars |
| Share Price | $ 0.00 |
| Closing Price Change | $ 0.00 |
| % Change | 0.00 % |
| 52 Week High | $0.00 |
| 52 Week Low | $0.00 |
| Volume | 0 |
| Shares Issued | 79.85m |
| RiskGrade | 337 |
You are here: research